Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells

Comprehensive analysis of kinase inhibitor selectivity

Mindy I. Davis, Jeremy P. Hunt, Sanna Herrgård et al. · Nature Biotechnology · 2011 · 2.4K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Avnish Kapoor, Wantong Yao, Haoqiang Ying et al. · Cell · 2014 · 728 citations · Full text

Medicine, Molecular Biology, Oncology +12

MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway

Zhipeng Meng, Toshiro Moroishi, Violaine Mottier-Pavie et al. · Nature Communications · 2015 · 536 citations · Full text

Life Sciences, Genetics, Molecular Biology +13

Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense

Kara G. Lassen, Petric Kuballa, Kara L. Conway et al. · Proceedings of the National Academy of Sciences · 2014 · 366 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

Weiying Zhang, Nivedita Nandakumar, Yuhao Shi et al. · Science Signaling · 2014 · 363 citations

Medicine, Molecular Genetics, Oncology +17